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Serine phosphorylationCD6 is a transmembrane receptor expressed by all T and a subset of B lymphocytes, where it phys-
ically associates with the antigen-speciﬁc receptor to modulate activation and differentiation pro-
cesses through still poorly understood mechanisms. Its cytoplasmic tail lacks intrinsic catalytic
activity but presents several consensus motifs for phosphorylation. The present work reports on
the identiﬁcation of two constitutively phosphorylated serine clusters (S480/482/484 and S560/
562/565/567/568), which are embedded into Casein Kinase 2 consensus motifs, and are indispensable
for proper mitogen-activated protein kinase activation following CD6 ligation. The data point to a
novel level of regulation of CD6 function by intracytoplasmic serine phosphorylation.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
CD6 is a 105–130 kDa transmembrane glycoprotein mainly ex-
pressed on T lymphocytes [1], but also on the B1a cell subset,
chronic lymphocytic leukemia B cells (B-CLL), NK cells, and hemo-
poietic precursors, as well as on certain brain regions [2]. This pro-
tein belongs to the scavenger receptor cysteine-rich superfamily
(SRCR-SF) [3], whose members are characterized by the presence
of one or several repeats of a highly conserved cysteine-rich pro-
tein module, known as the SRCR domain.
The CD6 gene maps to human chromosome 11 just centromeric
to the CD5 gene, another closely related member of the SRCR-SF,
which is thought to have arisen from duplication of a common
ancestor gene [4]. CD6 is composed of 13 exons, of which exons8 through 13 encode most the cytoplasmic region. The full-length
transcript encodes a 668-aa mature protein, although several
shorter alternatively spliced isoforms have been reported: one
lacking exon 5 (DSRCR3) in T cells [5], and several isoforms lacking
exons 8–12 in B-CLL [6].
To date, the function of CD6 is far from being completely under-
stood. Recent data indicate that its extracellular region is involved
in recognition of pathogen-associated molecular patterns (PAMPs)
mainly present in bacterial surfaces [7]. However, CD6 has classi-
cally been implicated in cell adhesion phenomena, mainly through
interaction of its most membrane-proximal extracellular domain
(SRCR3) with the most N-terminal domain of CD166/ALCAM (Acti-
vated Leukocyte Cell Adhesion Molecule), an adhesion molecule
belonging to the immunoglobulin (Ig) superfamily [8]. CD6 physi-
cally associates with the T-cell receptor (TCR)/CD3 complex and
co-localizes with it at the center of the immunological synapse
(IS), where its interaction with CD166/ALCAM results critical for
maturation and stabilization of the IS [9,10]. Taken together, all
these data support an important role for CD6 in the modulation
of T cell activation, either positively or negatively, in response to
both exogenous and endogenous antigens.
The signalling pathway used by CD6 is mostly unknown. CD6
has a long cytoplasmic tail devoid of intrinsic catalytic activity
but containing several signal-transducing consensus motifs [11].
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SH3 domain-binding consensus sequence, a Ser/Thr-rich motif re-
peated three times, three Protein Kinase C (PKC) phosphoryla-
tion-site motifs, 10 Casein Kinase 2 (CK2) phosphorylation site
motifs and nine Tyr residues [11]. This cytoplasmic tail is constitu-
tively phosphorylated [12], and becomes hyperphosphorylated on
Ser and Tyr residues upon T-cell activation [12–14]. Transient TCR-
mediated phosphorylation of Y629 and Y662 residues [15] is likely
mediated through interaction with protein tyrosine kinases from
the Src, Syk and Tec families [16]. Deletion and point-mutation
analyses have stressed the functional relevance of the C-terminal
region encompassing the Y629 and Y662 residues for CD6-medi-
ated mitogen-activated protein kinase (MAPK) pathway activation
[17], and recruitment of the positive regulator SLP-76 [18], as well
as the cytoskeleton scaffolding PDZ-containing protein Syntenin-1
[19], but not for intracellular calcium mobilization following CD6/
TCR co-ligation [15].
Regarding Ser/Thr phosphorylation of CD6, little information is
available on the precise residues involved and their functional role.
Biosynthesis studies have shown that the fully processed mature
CD6 form (130 kDa) from resting T cells and thymocytes is consti-
tutively phosphorylated on Ser residues and can be hyperphospho-
rylated when stimulated with PKC activators [20]. Moreover, the
130 kDa form has been shown to result from conversion of a
105 kDa form via Ser phosphorylation [12]. The present work
was aimed at the physical mapping of Ser residues involved in
the constitutive and inducible phosphorylation of CD6, as well as
to explore its putative functional relevance for intracellular signal-
ling. The data indicate that two Ser clusters embedded into consen-
sus sites for CK2 (S480/482/484 and S560/562/565/567/568)
contribute to the constitutive phosphorylation of CD6 and are
important for ligand-induced CD6-mediated MAPK activation.
These Ser clusters are absent in some cytoplasmic isoforms of
CD6 and are reminiscent of a similar CK2 motif identiﬁed on the
CD5 receptor [21,22], which is involved in CD5-mediated modula-
tion of TCR signalling [23]. The potential of these sites as a new reg-
ulatory mechanism of CD6 function is discussed.Fig. 1. Schematic representation of the CD6 molecules used in this study. (A) Distributio
the CD6 cytoplasmic region. Residues embedded into consensus phosphorylation and si
Ca2+/Calmodulin-dependent protein kinase. (B) CD6 variants used in this work are name
Serto Ala substitutions were introduced.2. Materials and methods
2.1. Cells
COS7 cells were obtained from the American Tissue Culture Col-
lection. Stable CHO transfectants producing ALCAM-Fc were kindly
provided by Dr. Carl Figdor (Radboud University Medical Centre,
Nijmegen, The Netherlands). The CD5- and CD6-negative Jurkat
cell line derivative (2G5 cells) has been reported elsewhere [24].
Human Peripheral Blood Mononuclear Cells (PBMCs) were ob-
tained from whole blood of healthy volunteers by standard density
gradient centrifugation. Stable 2G5 Jurkat cell transfectants
expressing wild-type and cytoplasmic tail-truncated mutant CD6
molecules (Fig. 1B) were generated as described [24]. COS7 cells
were transiently transfected with Lipofectamine 2000 (Invitrogen
Life Technologies) following the manufacturer’s instructions.
2.2. Generation of cDNA eukaryotic expression constructions
Construction of expression plasmids coding for cytoplasmic
tail-truncated (CD6.V463stop, CD6.P524stop and CD6.A613stop) and
wild-type (CD6.WT) CD6 proteins has been reported elsewhere
[9,19,25]. The constructs pHb-CD6.P524stopS480/482/484A and
pHb-CD6.S480/482/484A in which Ser 480, 482 and 484 have been
replaced by Ala were generated by site directed mutagenesis using
the QuikChange XL-Site-Directed Mutagenesis kit (Stratagene, La
Jolla, CA) and the sense 50-CCTGAGGACTCAGACGCTGGCGCGGAC
GCAGACTAT GAGCACT-30 and antisense 50-AGTGCTCATAGTCTG
CGTCCGCGCCAGCGTCTGAGTCCTCAGG-30 oligonucleotides, in
which the nucleotide changes responsible for amino acid substitu-
tions are underlined.
For generation of the pHb-CD6.S560/562/565/567/568A and
pHb-CD6.S480/482/484A-S560/562/565/567/568A constructs, the
whole transmembrane and cytoplasmic cDNA sequence of CD6
containing Ser to Ala substitutions at positions 560, 562, 565,
567, 568 and/or 480, 482 and 484 as well as 50 EcoRI and 30 BamHI
restriction sites, was synthesized and cloned into pUC57 byn of exon boundaries and of serine (S), threonine (T) and tyrosine (Y) residues along
gnal transduction motifs are highlighted. PKA/G/C, Protein Kinase A, G or C; CaMK,
d according to the residue of the mature protein in which a premature stop and/or
Fig. 2. Analysis of constitutive and PMA-inducible Ser phosphorylation of wild-type
and truncated CD6 molecules. (A) Serum-starved stable Jurkat 2G5 cell transfec-
tants (5  106 cells/well) expressing wild-type (CD6.WT) or truncated
(CD6.V463stop, CD6.P524stop, CD6.A613stop) molecules were incubated for 1 h at
37 C with (+) or without () PMA (60 ng/ml). CD6 immunoprecipitates were then
sequentially Western blotted with anti-pSer and anti-CD6 antisera. The densitom-
etry of bands from four independent experiments is shown and expressed as the
mean ± SD of the pSer/CD6 ratio, considering 1.0 as the value for the PMA-
stimulated CD6.WT. (B) Cell lysates (15 lg) from PMA-stimulated (+) or unstim-
ulated () transfectants used in (A) were sequentially Western blotted with anti-
pERK1/2 and -tERK1/2 antisera. Fig. 3. Mutation of the S480/482/484 cluster abrogates constitutive phosphoryla-
tion of CD6.P524stop. (A) Serum-starved COS7 transfectants (2  105 cells/well)
transiently expressing CD6.P524stop or its mutated version (CD6.P524stopS480/482/
484A) were incubated for 1 h at 37 C with (+) or without () PMA (60 ng/mL). CD6
immunoprecipitates were then sequentially Western blotted with anti-pSer and
anti-CD6 antisera. Shown is the densitometry of bands considering 1.0 as the pSer/
CD6 ratio of untreated transfectants. One experiment of two performed is shown.
(B) Cell lysates (15 lg) from PMA-stimulated (+) or unstimulated () transfectants
used in (A) were sequentially Western blotted with anti-pERK1/2 and -tERK1/2
antisera.
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ampliﬁed and cloned into EcoRI and BamHI restricted pHb-CD6.WT
construct for replacement of the wild-type cytoplasmic region.
2.3. CD6 and MAPK phosphorylation analysis
Constitutive and inducible Ser phosphorylation of wild-type
and mutant CD6 molecules was analyzed by incubating serum-
starved 2G5 Jurkat or COS7 cells for 1 h in the presence or absence
of Phorbol 12-myristate 13-acetate (PMA). Next, CD6 was immu-
noprecipitated from detergent cell solubilizates by means of the
161.8 mAb plus protein A Sepharose. The phosphoserine (pSer)
content was assayed by Western blot with a rabbit anti-pSer anti-
serum (Ref. 61-8100, Invitrogen Life Technologies, Carlsbad, CA)
plus horseradish peroxidase (HRP)-linked Whole ECL™ anti-rabbit
IgG antiserum and then developed by chemiluminescence. For
detection of CD6, blots were stripped and then incubated a rabbit
polyclonal antiserum against the extracellular region of human
CD6 plus HRP-linked whole anti-rabbit IgG antiserum. The results
are expressed as the ratio of the intensity of the bands correspond-
ing to pSer and CD6. P-values compare stimulated to baseline pSer/
CD6 ratios for each CD6 variant.
ForMAPKactivation, serum-starved transientCOS7 transfectants
expressing wild-type or mutant CD6 molecules were incubated in
the presence or absence of anti-CD6 mAb, PMA, lipopolysaccharide
(LPS) or plate-boundALCAM-Fcprotein. Treated cellswere then sub-
jected toWestern blot analysis to determine the content of phospho
(p)ERK1/2 and pMEK1/2 relative to total (t)ERK1/2 and tMEK1/2,
respectively. P-values compare differences between (pERK1/2)/
(tERK1/2) ratios in wild-type and mutated CD6 proteins.
In all cases the densitometric analysis was performed using
Image J software (National Institutes of Health, http://rsb.info.nih.-
gov/ij/).2.4. CK2 assays
For heparin-induced CK2 inhibition assays, serum-starved 2G5
and COS7 transfectants expressing full-length wild-type and mu-
tant CD6 molecules were incubated with different heparin concen-
trations (0–50 lg/ml) for different periods of time (0–24 h). Then
the cells were lysed, and CD6 immunoprecipitated for further anal-
ysis of pSer content by Western blot.
In vitro kinase assays of CD6.P524stop from stable 2G5 transfec-
tants were performed by ﬁrst treating immunoprecipitates with
10 U of alkaline phosphatase, and then with puriﬁed CK2 (50 U)
(New England Biolabs, UK) plus ATP (200 lM) in the presence or
absence of heparin (5 mg/ml). A negative control where only ATP
was added to the immunoprecipitates in the presence of CK2 buffer
was also included. Detection of pSer levels on CD6 immunoprecip-
itates was carried out by Western blot.
3. Results and discussion
3.1. Identiﬁcation of constitutive and inducible Ser phosphorylation
sites in the CD6 cytoplasmic region
The intracytoplasmic tail of CD6 contains multiple Ser residues
embedded into consensus motifs putatively targeted by different
Fig. 4. Heparin effects on in vitro phosphorylation of CD6.P524stop. (A) Dose-dependent inhibition of constitutive Ser phosphorylation of CD6.P524stop by heparin. Stable
Jurkat 2G5 transfectants (5  106 cells/well) expressing CD6.P524stop were incubated for 90 min with increasing doses (0, 10 or 20 lg/ml) of heparin. CD6
immunoprecipitates were sequentially Western blotted with anti-pSer and anti-CD6 antisera. Shown is the densitometry of bands considering 1.0 as the pSer/CD6 ratio
of untreated transfectants. (B) Time-dependent inhibition of constitutive Ser phosphorylation of CD6.P524stop by heparin. The same analysis as in (A) was performed except
that transfectants were incubated for 0, 4 or 24 h in the presence of heparin (15 lg/ml). The experiments presented in (A) and (B) are representative of two performed. (C) In
vitro CK2 assays of CD6.P524stop. CD6 immunoprecipitates from stable 2G5 Jurkat transfectants (5  106 cells) expressing CD6.P524stop were treated (+) or not () with
alkaline phosphatase (AP, 10 U) for 1 h at 37 C and then incubated for 1 h at 30 C with (+) or without () CK2 (50 U) plus ATP (200 lM) in the presence (+) or absence () of
heparin (5 mg/ml). The immunecomplexes were then sequentially Western blotted with anti-pSer and anti-CD6 antisera. Shown is a representative experiment of two
performed.
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and inducible Ser-based phosphorylation sites, constructs express-
ing truncated forms of CD6 (CD6.V463stop, CD6.P524stop, and
CD6.A613stop) (Fig. 1B) were generated and stably expressed on
2G5 cells, a variant of the Jurkat T-cell line with undetectable
CD6 and CD5 expression [24]. The pSer content of the respective
CD6 tail-truncated forms was analyzed upon incubation with
PMA, a potent activator of the Ser/Thr kinase PKC. As illustrated
by Fig. 2A (top panel), pSer was observed for wild-type CD6
(CD6.WT) as well as for the two most C-terminal truncated vari-
ants (CD6.P524stop, and CD6.A613stop) under both basal and post-
PMA stimulation conditions. However, the shortest CD6 variant
analyzed (CD6.V463stop) showed undetectable pSer either pre- or
post-PMA stimulation (Fig. 2A, top panel), indicating that Ser resi-
dues suitable for constitutive and inducible phosphorylation of
CD6 lay somewhere between residues V463 and P524 or beyond.
The possibility that CD6.V463stop transfectants were insensitive
to PMA-stimulation and phosphorylation was excluded by the
analysis of pERK1/2 levels pre- and post-PMA stimulation
(Fig. 2B). Furthermore, a signiﬁcant increase of pSer levels follow-
ing PMA-stimulation with regard to basal values could be observed
for the CD6.WT and CD6.A613stop variants, but not CD6.P524stop
nor CD6.V463stop (Fig. 2A, bottom panel). This indicates the pres-
ence of putative PMA-inducible pSer sites somewhere between
positions P524 and A613.
The cytoplasmic region encompassing V463 and P524 contains
four Ser residues embedded into phosphorylation consensus mo-
tifs for the Ser/Thr protein kinases CK2 (S480, S482 and S484)
and PKC (S505) (Fig. 1A). A new variant of CD6.P524stop was thengenerated in which Ser to Ala substitutions were introduced at
positions 480, 482 and 484 (CD6.P524stopS480/482/484A). Then,
mutated and unmutated versions of CD6.P524stop were transiently
transfected into COS7 cells for further analysis. As shown by
Fig. 3A, pSer was undetectable on the CD6.P524stopS480/482/
484A variant under both basal and PMA-stimulation conditions.
As a control, no differences were detected between the two trans-
fectants (CD6.P524stop and CD6.P524stopS480/482/484A) regarding
the pERK1/2 levels before and after PMA stimulation (Fig. 3B). Ta-
ken together, these data indicate that S505, which is embedded
into a putative PKC consensus site, is dispensable for both the con-
stitutive and PMA-inducible phosphorylation of CD6. By contrast,
the S480/482/484 cluster is relevant to constitutive but not induc-
ible Ser phosphorylation of CD6. Moreover, the results also indicate
that one or several consensus motifs for Ser/Thr protein kinases lo-
cated between residues P524 and A613 could account for PMA-
inducible Ser phosphorylation of CD6.
3.2. In vitro phosphorylation analysis of membrane-proximal S480/
482/484 cluster by CK2
The phosphorylatable membrane-proximal S480/482/484 clus-
ter of CD6 is very similar to another cluster (S458/459/461) present
on the C-terminal cytoplasmic region of CD5, which is known to be
targeted by CK2 and is responsible not only for constitutive phos-
phorylation but also regulation of CD5 function [21–23]. It is worth
noting that CD5 physically associates to CK2 (through binding of
the regulatory b subunit of CK2 to the S458/459/461 cluster), and
in turn CD5 is physically associated to CD6 as well [25]. In light
Fig. 5. Integrity of the S480/482/484 cluster is relevant to MAPK activation via CD6. (A) CD6 immunoprecipitates from serum-starved COS7 cells (2  105 cells/well)
transiently transfected with full-length wild-type (CD6.WT) or mutated (CD6.S480/482A/484A) molecules were sequentially Western blotted with anti-pSer and anti-CD6
antisera. Shown is the densitometry of bands considering 1.0 as the pSer/CD6 ratio for CD6.WT molecules. (B) The same COS7 transfectants as in (A) were incubated for 1 h at
37 C with or without anti-CD6 161.8 mAb (10 lg/ml) or PMA (60 ng/ml). Cell lysates (15 lg protein) were sequentially Western blotted with antisera to phosphorylated (p)
and total (t) ERK1/2 or MEK1/2. Shown is the densitometry of bands considering 1.0 as the pERK/tERK or pMEK/tMEK ratios for CD6.WT stimulated with a-CD6 or PMA. (C and
D) The same cell transfectants as in (A) and (B), as well as mock-transfected COS7 cells (MOCK), were incubated for 40 min or 1 h at 37 C with LPS (50 lg/ml) or plate-bound
ALCAM-Fc (30 lg/ml), respectively. Cell lysates were then Western blotted as in (B). The experiment shown is representative of two performed.
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Ser phosphorylation of CD6 was investigated using heparin, a
non-speciﬁc CK2 inhibitor. As shown by Fig. 4A and B, heparin
caused a dose- and time-dependent reduction on pSer levels in sta-
bly CD6.P524stop-transfected Jurkat 2G5 cells. Furthermore, hepa-
rin inhibited CD6.P524stop Ser phosphorylation by puriﬁed CK2 in
an in vitro kinase assay (Fig. 4C, left panel). Control experiments ex-
cluded the possible presence of CK2 or any other Ser kinase consti-
tutively associated with this CD6 variant (Fig. 4C, right panel).
Altogether, these data point to an implication of CK2 in constitu-
tive CD6 Ser phosphorylation. This could be achieved through tar-
geting of CK2 to plasma membrane via its known association with
CD5 or any other surface receptor. Alternatively, the possibility ex-
ists that CK2 could also directly associate to CD6 through binding
to the S480/482/484 region. While this possibility remains to be
unequivocally dismissed, no evidence for any kinase activity asso-
ciated to CD6 has been reported so far. Accordingly, our in vitro ki-
nase assay showed lack of detectable pSer on CD6.P524stopimmunoprecipitates in the presence of ATP but in the absence of
an exogenously added kinase.
3.3. Integrity of the membrane-proximal S480/482/484 cluster of CD6
is relevant forligand-induced CD6 intracellular signalling
The CD6 signalling pathway involves activation of theMAPK cas-
cade following cross-linking by either anti-CD6 monoclonal anti-
bodies (mAbs), or by endogenous or exogenous ligands, such as
ALCAM/CD166 [17] or bacterial LPS [7], respectively. To explore
the functional relevance of the constitutively phosphorylated Ser
cluster here identiﬁed, full-length CD6 molecules containing Ser to
Ala substitutions at positions 480, 482 and 484 (CD6.S480/482/
484A) were transiently expressed on COS7 cells. Experiments
showed that the constitutive pSer level of CD6.S480/482/484A
immunoprecipitates was indeed lower than that of CD6.WT
(Fig. 5A). Furthermore, stimulation with anti-CD6 also resulted in
lowerpERK1/2andpMEK1/2 levels inCOS7 transfectants expressing
Fig. 6. The S560/562/565/567/568 cluster is constitutively phosphorylated. CD6
immunoprecipitates from serum-starved COS7 cells (2  105 cells/well) transiently
expressing full-length wild-type (WT) or mutated (CD6.S480/482/484A, CD6.S560/
562/565/567/568A, and CD6.S480/482/484A-S560/562/565/567/568A) molecules
were Western blotted with anti-pSer and anti-CD6 antisera. Shown is the
densitometry of bands considering 1.0 as the pSer/CD6 ratio of CD6.WT molecules.
The experiment shown is representative of two performed.
Fig. 7. Heparin affects the constitutive phosphorylation of the S560/562/565/567/
568 cluster. Serum-starved COS7 cells (2  105 cells/well) transiently expressing
full-length wild-type (WT) or mutated (CD6.S480/482/484A, CD6.S560/562/565/
567/568A, and CD6.S480/482/484A-S560/562/565/567/568A) molecules were
treated with heparin (50 lg/ml) for 24 h. Then, CD6 immunoprecipitates were
sequentially Western blotted with anti-pSer and anti-CD6 antisera. Shown is the
densitometry of the bands considering 1.0 as the pSer/CD6 ratio of CD6.WT
molecules. The experiment shown is representative of two performed.
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(Fig. 5B). This result shows that the MAPK pathway is inducible in
a non-lymphoid cell line such as COS7 by CD6 stimulation,supporting our use of these cells as an experimentalmodel. Further-
more, these differences were not observed when the transfectants
were stimulated with PMA, a strong MAPK cascade activator that
by-passes CD6, thus indicating that they are not due to intrinsic de-
fects on the MAPK cascade but speciﬁc to the CD6 variant cross-
linked. Similar differences in pERK1/2 activation were observed
when the same transfectants were stimulated with either soluble
LPS or solid-phase boundALCAM-Fc (Fig. 5C andD, respectively). Ta-
ken together, these results indicate that the constitutively phos-
phorylated membrane-proximal S480/482/484 cluster is relevant
to proper intracellular signalling via CD6, as deduced from the anal-
ysis of the MAPK cascade activation under both high- (anti-CD6
mAb) and low- (ALCAM-Fc or LPS) avidity cross-linking conditions.
3.4. Identiﬁcation of a second constitutively phosphorylated and
functionally relevant membrane-distal Ser cluster in the cytoplasmic
region of CD6
The fact that pSer levels of CD6.S480/482/484A-transfected
cells were not completely abolished (Fig. 5A) suggested that addi-
tional constitutive pSer sites exist in the cytoplasmic region of CD6
beyond P524. Sequence analysis of this region revealed an
additional Ser cluster (S560/562/565/567/568) embedded into
CK2-consensus motifs (Fig. 1A). Thus, full-length variants were
generated in which Ser to Ala substitutions were introduced in
such a membrane-distal Ser cluster, either alone (CD6.S560/562/
565/567/568A) or in combination with that of the membrane-
proximal Ser cluster (CD6.S480/482/484A-S560/562/565/567/
568A). As illustrated by Fig. 6, CD6.S560/562/565/567/568A immu-
noprecipitates from unstimulated cells showed lower constitutive
pSer levels than those of CD6.WT but similar to CD6.S480/482/
484A. As expected, CD6.S480/482/484A-S560/562/565/567/568A
immunoprecipitates showed additive effects with regard to muta-
tion of either cluster alone. These results indicate that the S560/
562/565/567/568 cluster represents a second major site for consti-
tutive phosphorylation of CD6, even though additional Ser residues
might also be involved. Remarkably, Fig. 6 also shows that
CD6.S560/562/565/567/568A molecules have a faster electropho-
retic mobility than CD6.WT or CD6.S480/482/484A in spite of
having the same predicted molecular weight. Therefore, the data
indicate that the S560/562/565/567/568 cluster is involved in the
reported phosphorylation-dependent interconversion from the
105 kDa to the 130 kDa form of CD6 [12]. The nascent 88 kDa
CD6 polypeptide from T cells is converted into an immature N-gly-
cosylated 105 kDa form, which is then further O-glycosylated to a
mature 130 kDa form [20]. Interestingly, only the 130 kDa form is
phosphorylated and rends the 105 kDa form following alkaline
phosphatase treatment [12]. Thus, the conversion from 105 to
130 kDa, although coincidental with O-glycosylation changes, is
most likely due to phosphorylation, as supported by its relative
resistance to tunicaycin treatment [20]. From these and our data,
it can be inferred that phosphorylation of the S560/562/565/567/
568 cluster is responsible for the well-documented electrophoretic
mobility shift of the CD6 receptor.
Further experiments showed that heparin importantly reduced
the basal pSer content of CD6.WT, CD6.S480/482/484A, and
CD6.S560/562/565/567/568A molecules but not that of CD6.S480/
482/484A-S560/562/565/567/568A (Fig. 7), suggesting involve-
ment of CK2 in the phosphorylation of these Ser clusters.
In another set of experiments, cross-linking of CD6.S560/562/
565/567/568A-expressing COS7 transfectants by anti-CD6 mAb,
soluble LPS or plate-bound ALCAM-Fc (Fig. 8A–C, respectively) re-
sulted in reduced ERK1/2 activation compared to CD6.WT. This
reduction was similar to that observed for CD6.S480/482/484A
and CD6.S480/482/484A-S560/562/565/567/568A transfectants,
thus supporting their functional relevance.
Fig. 8. Integrity of the S560/562/565/567/568 cluster is functionally relevant to CD6-mediated MAPK activation. (A and B) Serum-starved COS7 cells (2  105 cells/well)
transiently expressing full-length wild-type (WT) or mutated (CD6.S480/482/484A, CD6.S560/562/565/567/568A, CD6.S480/482/484A-S560/562/565/567/568A) CD6
molecules were incubated with or without anti-CD6 161.8 mAb (10 lg/ml) or LPS (50 lg/ml) for 1 h or 40 min at 37 C, respectively. Cell lysates (5 lg protein) were Western
blotted with antisera to pERK1/2, tERK1/2 or CD6. Shown is the densitometry of bands considering 1.0 as the pERK/tERK corrected by CD6 expression for the CD6.WT
transfectant. (C) Same COS7 transfectants as in (A) and (B) were incubated with plate-bound ALCAM-Fc (20 lg/ml) for 1 h at 37 C. Cell lysates were Western blotted as in (A)
and (B). The result shown is representative of two experiments.
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Fig. 9. Schematic representation of alternatively spliced CD6 isoforms. (A) Summary of the alternatively spliced human and mouse CD6 transcripts reported in the literature.
CD6a is the largest and most abundant human (and mouse) isoform [6]. CD6a-b isoforms were isolated from phytohemagglutinin-activated human PBMCs, and CD6a-e from
B-CLL cells [6]. CD6-15 was from a human acute lymphocytic leukemia (HPB-ALL) and results from a cryptic splice acceptor site in exon 9 causing a premature stop [1]. m-
CD6 was isolated from mouse thymocytes [27]. CD6Dd3 was isolated from rat and human thymocytes and peripheral T cells [5]. CD6 gene exons are depicted as boxes and
numbered from 1 to 13. Deleted exons are depicted as empty red boxes. (B) Representation of the three alternatively spliced cytoplasmic CD6 isoforms (besides of CD6a)
found by our group from mitogen-activated human PBMCs.
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Altogether, these ﬁndings support the notion that both mem-
brane-proximal and -distal Ser clusters are major sites for constitu-
tive Ser phosphorylation of CD6, and that both are functionally
relevant since disruption of either one results in MAPK activation
defects upon CD6 ligation.
Besides the identiﬁcation of the constitutively phosphorylated
S480/482/484 and S560/562/565/567/568 clusters, this study also
provides evidence of the existence of PMA-inducible Ser phosphor-
ylation site/s located at the region encompassing amino acids P524
to A613. The in silico analysis of this amino acid region reveals the
presence of two Ser residues (S575 and S590) embedded into con-
sensus motifs for PKC (Fig. 1A). The absence of similar predictable
PKC-consensus sites beyond A613, makes S575 and/or S590 the
most likely PKC-phosphorylatable sites at the CD6 cytoplasmic re-
gion, discarding S505 through our analysis of the mutated
CD6.P524stop construct (Fig. 3). However, further mutational anal-
ysis is needed to fully ascertain the targeting of S575 and/or S590
by PKC as well as its functional consequences.
The fact that mutation of either S480/482/484 or S560/562/565/
567/568 clusters results in attenuation of CD6-mediated MAPK
activation opens the possibility that phosphorylation of either site
constitutes an alternative mechanism for regulating CD6 function.
This is relevant to the most accepted function of the CD6 receptor:
the modulation of lymphocyte activation and differentiation sig-
nals triggered via antigen-speciﬁc recognition. The ﬁne tuning of
those signals is critical to determining either survival or death of
antigen-challenged lymphocytes. Accordingly, a successful CD6-
ALCAM/CD166 interaction has been shown to be critical for proper
T cell activation and proliferation induced by antigen presenting
cells [9,26].
Therefore, it seems likely that altering the signal transduction
ability of the CD6 receptor may also inﬂuence the lymphocyte acti-
vation status when CD6 is cross-linked. This could occur by the re-
ported alternative splicing of the ALCAM-binding SRCR3 domain
during T cell maturation and activation [5]. Alternatively, splicing
isoforms of CD6 involving deletions of intracellular region seg-
ments could also affect CD6 signalling and function. Some of these
isoforms have already been described and include deletions in
exon 9 and 11, where the Ser clusters here described are encoded
(Fig. 9). It could then be speculated that exclusion of either Ser
cluster might be a new putative molecular mechanism for regulat-
ing CD6 signalling.Competing interests
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